Author/Authors :
فاضلي، يوسف نويسنده Agricultural, Medical and Industrial Research School, Nuclear Science and Technology Research Institute, Atomic Energy Organization of Iran, Karaj, I Fazaeli, Yousef , جليليان ، اميررضا نويسنده Jalilian, A.R , اميني، مصطفي نويسنده , , ميرزايي، محمد نويسنده mirzaee, mohammad , مجدآبادي ، عباس نويسنده Majdabadi, A , اصلاني كردكندي، غلامرضا نويسنده , , محمدرضا رحيمي نژاد، علي اصغر معصومي نويسنده , , بلوري نوين، فاطمه نويسنده سازمان انرژي اتمي ايران,پژوهشگاه علوم و فنون هسته اي , , مرادخاني، صديقه نويسنده سازمان انرژي اتمي ايران Moradkhani, S
Abstract :
Introduction: Due to the interesting pharmacological properties of radiolabeled metal oxine derivatives such as
cell internalization, tumor avidity and antiproteosome activity, 111In-tris[8-Hydroxy-2-methylquinoline] (111In-
HMQ) was developed in this study.
Methods: 111In-HMQ was prepared using 111InCl3 and 8-Hydroxy-2-methylquinoline (HMQ) for 60 min at
100?C (radiochemical purity: > 99% ITLC, > 99% HPLC, specific activity: 13-14 GBq/mmol). Stability of the
complex was checked in final formulation and in the presence of human serum for 48 h. The partition
coefficient was calculated for the compound (log P=0.68).
Results: The biodistribution of the labeled compound in vital organs of wild-type rats was studied using
scarification studies and SPECT up to 24 h. A detailed comparative pharmacokinetic study for 111In cation and
111In-HMQ are performed up to 24h.
Conclusion: The complex is mostly cleaned from the circulation by kidneys and is a compound rapidly washing
from the circulation. The biodistribution of the complex in tumor models is on-going.
